Tenet Healthcare (Tenet Healthcare) Cash And Cash Equivalents

: $1,228 Mil (As of Dec. 2023)

View and export this data going back to 1976. Start your Free Trial

Tenet Healthcare's quarterly cash and cash equivalents increased from Jun. 2023 ($934.00 Mil) to Sep. 2023 ($1,054.00 Mil) and increased from Sep. 2023 ($1,054.00 Mil) to Dec. 2023 ($1,228.00 Mil).

Tenet Healthcare's annual cash and cash equivalents declined from Dec. 2021 ($2,364.00 Mil) to Dec. 2022 ($858.00 Mil) but then increased from Dec. 2022 ($858.00 Mil) to Dec. 2023 ($1,228.00 Mil).

Tenet Healthcare Cash And Cash Equivalents Historical Data

The historical data trend for Tenet Healthcare's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenet Healthcare Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

262.00

2,446.00

2,364.00

858.00

1,228.00

Tenet Healthcare Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															858.00	766.00	934.00	1,054.00	1,228.00

Tenet Healthcare Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Tenet Healthcare (NYSE:THC) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Tenet Healthcare Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Tenet Healthcare's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Tenet Healthcare (Tenet Healthcare) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Tenet Healthcare Corp (NYSE:THC) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

THC:Mexico THC1:Germany

Address

14201 Dallas Parkway, Dallas, TX, USA, 75254

Website

https://www.tenethealth.com

Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 60 as of June 2023) and over 550 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.

Executives

Richard W Fisher	director
Roy Blunt	director	2702 LOVE FIELD DRIVE, HDQ 4GC, DALLAS TX 75235
Paola M Arbour	officer: EVP, Chief Information Officer	14201 DALLAS PARKWAY, DALLAS TX 75254
Stephen H Rusckowski	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Thomas W Arnst	officer: EVP, Chief Admin. Officer & GC	14201 DALLAS PARKWAY, DALLAS TX 75254
Tammy Romo	director	C/O SOUTHWEST AIRINES CO., 2702 LOVE FIELD DR., DALLAS TX 75235
Daniel J Cancelmi	officer: Principal Accounting Officer	13737 NOEL ROAD, SUITE 100, DALLAS TX 75240
J Robert Kerrey	director	NEW SCHOOL UNIVERSITY, 66 W. 12TH STREET, NEW YORK NY 10036
Richard J Mark	director	1901 CHOUTEAU AVENUE MC-1310, ST. LOUIS MO 63103
Ronald A Rittenmeyer	director	5400 LEGACY DRIVE, PLANO TX 75024
Lisa Y Foo	officer: EVP, Commercial Ops	14201 DALLAS PARKWAY, DALLAS TX 75254
Audrey T. Andrews	officer: SVP and General Counsel	1445 ROSS AVENUE, SUITE 1400, DALLAS TX 75202
Meghan Fitzgerald	director	C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Howard Hacker	officer: EVP, Chief Compliance Officer	14201 DALLAS PARKWAY, DALLAS TX 75254
Marie Quintana	officer: EVP, Marketing/Communications	14201 DALLAS PARKWAY, DALLAS TX 75254